GS-5829
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for GS-5829, covering 2019-08-07 to 2020-12-08. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer [Phase 1, Phase 2]